Merck aims for prostate cancer dominance with 3 new phase 3 Keytruda studies

Keytruda
Merck says it now has the largest prostate cancer development program for PD-1/PD-L1 drugs. (Merck)

If Merck & Co. gets its way, it won’t be long before the prostate cancer treatment landscape looks pretty different.

After fielding promising early results for immuno-oncology star Keytruda in metastatic, castration-resistant forms of the disease, the New Jersey drugmaker is adding a trio of late-stage studies to its Keytruda program, hoping they'll deliver some combo approvals.

Merck will run phase 3 studies testing its standout drug in tandem with Lynparza, the PARP inhibitor it shares with AstraZeneca; in a cocktail containing the chemotherapy docetaxel and steroid prednisone; and alongside Xtandi, a hot prostate cancer drug from Pfizer and Astellas.

3-Day Conference

6th Promotional Review Committee Compliance & Best Practices Conference

The leading U.S. event devoted to building the skills, speed and teamwork of your promotional review committee members will take place May 15–17, 2019 in Chicago. The conference is set to bring together more than 75 professionals to ensure your PRC is prepared to generate, collect and constructively act on expert comments for your entire drug and device portfolio.

The move comes on the back of positive data from the phase 1b/2 Keynote-365 trial that Merck trotted out Thursday morning. In the cohort of patients receiving the Keytruda-Lynparza duo, 12% recorded a decrease of 50% or more in prostatic specific antigen, a protein whose levels are often elevated in men with prostate cancer. The Keytruda-docetaxel-prednisone regimen produced a PSA response rate of 31%, while the Keytruda-Xtandi posted a rate of 26%.

RELATED: AstraZeneca pioneer Lynparza scores with Zytiga combo in prostate cancer

In each of the groups, at the six-month mark, more than 70% of patients had survived, and in the docetaxel-prednisone and Xtandi groups, more than 90% of patients were still alive.

Of course, Merck isn’t the only company that’s testing its PD-1/PD-L1 drug in prostate cancer—or its PARP inhibitor, for that matter. In 2017, archrival Bristol-Myers Squibb teamed up with PARP drugmaker Clovis Oncology for a phase two prostate cancer test of Opdivo and Rubraca, and BMS has Opdivo going in a number of other prostate cancer trials, too.

RELATED: With Clovis team-up, Bristol-Myers' Opdivo eyes dynamic-duo attack on a trio of cancers

And Thursday, Johnson & Johnson trumpeted phase 2 data showing that Zejula—the third major player in the PARP class, and a drug to which it owns the rights in prostate cancer—could provoke a response in about 40% of mCRPC patients with BRCA mutations.

But Merck is aiming to show up its rivals. The addition of the three new studies will give it the largest development program with a PD-1/PD-L1 drug in prostate cancer, and it’ll also make it the only drugmaker to feature overall survival—considered the gold standard in cancer trials—as a coprimary endpoint through phase 3 trials.

Suggested Articles

The FDA has handed down its decision against Sanofi and Lexicon's Zynquista.

Analysts with Cortellis expect seven blockbuster drug launches in markets across the world this year. AbbVie's upadacitinib leads the pack.

The new Alcon shares will be listed on the Swiss Exchange and the New York Stock Exchange on April 9 under the ticker “ALC.”